GENELUX Corp
GNLX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.00
KIRA · Stoqly’s AI analyst, in plain words
- GENELUX Corp had $0.0M of revenue in fiscal 2025, up 0.0% on the year before.
- Its operating margin was −415,175.0%, down 18,975.0 pts: of every 100 in sales, about −415,175 is left after running the business.
- GENELUX Corp lost $32.1M in fiscal 2025.
- Free cash flow was −$26.4M in fiscal 2025, −329,575.0% of revenue.
Market cap
$89.9M
P/E
—
Revenue
$0.0M
Net income
−$32.1M
Free cash flow
−$26.4M
Operating margin
−415,175.0%
GENELUX Corp in 30 seconds · fiscal 2025
Are sales growing?
0.0%
Only a little. Sales grew 0.0% last year.
Does it make a profit?
−401,812.5%
No. It lost money last year.
Does profit turn into cash?
−329,575.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What GENELUX Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- GENELUX Corp
- CIK
- 0001231457
GENELUX Corp · GNLX
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $11.1M | $0.2M | $0.0M | $0.0M |
| Revenue growth | — | −98.5% | −95.3% | 0.0% |
| Operating margin | −27.2% | −14,214.7% | −396,200.0% | −415,175.0% |
| Net income | −$5.2M | −$28.3M | −$29.9M | −$32.1M |
| Net margin | −47.0% | −16,645.3% | −373,362.5% | −401,812.5% |
| Diluted EPS | −$0.57 | −$1.16 | −$0.95 | −$0.86 |
| Cash | ||||
| Cash from operations | −$3.6M | −$20.3M | −$21.2M | −$25.3M |
| Capital expenditure | $0.0M | $1.0M | $0.4M | $1.1M |
| Free cash flow | −$3.6M | −$21.3M | −$21.6M | −$26.4M |
| FCF margin | −32.7% | −12,529.4% | −270,112.5% | −329,575.0% |
| Share count change | — | 168.0% | 28.7% | 18.2% |
| Debt and strength | ||||
| Cash and short-term investments | $0.4M | $23.2M | $30.9M | $5.3M |
| Debt incl. finance leases | — | $0.9M | — | — |
| Shareholders' equity | −$35.8M | $19.5M | $26.3M | $11.5M |
| Current ratio | 0.1x | 3.7x | 4.6x | 2.4x |
| Interest coverage | — | −139.7x | — | — |
| Returns and quality | ||||
| Return on equity | — | — | −130.6% | −170.0% |
| Return on tangible equity | — | −145.3% | −113.7% | −278.5% |
| Piotroski F-score | — | 2 | 3 | 2 |
| Altman Z'' | −151.7 | −25.1 | −21.8 | −55.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
6 insiders
Of sales under plans
30%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GENELUX Corp · GNLX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.00 a share, the company is worth $89.9M.
Source: SEC EDGAR XBRL filings (CIK 0001231457). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.